Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency.
cortisone acetate
hydrocortisone
metabolic outcome
secondary adrenal insufficiency
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
01 Dec 2020
01 Dec 2020
Historique:
received:
09
06
2020
entrez:
26
11
2020
pubmed:
27
11
2020
medline:
27
11
2020
Statut:
epublish
Résumé
Pharmacokinetic properties of cortisone acetate (CA) and hydrocortisone (HC) differ because CA needs to be converted into cortisol to become active. This work analyzed the metabolic consequences of switching CA to an equivalent daily dose of HC in patients with secondary adrenal insufficiency (SAI). This was a post hoc analysis from a prospective study including individuals with hypopituitarism receiving growth hormone replacement. Data were collected before and after a switch from CA to an equivalent dose of HC (switch group). Two control groups were included: patients continuing CA replacement (CA control group) and adrenal-sufficient hypopituitary patients (AS control group). The analysis included 229 patients: 105, 31, and 93 in the switch, CA control, and AS control groups, respectively. After the change from CA to HC, increases in mean body weight (1.2 kg; A switch from CA to an equivalent dose of HC was associated with a worsened metabolic profile, suggesting that HC has a more powerful metabolic action than CA based on the assumption that 20 mg HC equals 25 mg CA.
Identifiants
pubmed: 33241171
doi: 10.1210/jendso/bvaa160
pii: bvaa160
pmc: PMC7671249
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvaa160Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Br J Clin Pharmacol. 1984 Jan;17(1):55-9
pubmed: 6691888
Calif Med. 1958 Jun;88(6):417-22
pubmed: 13536856
Eur J Endocrinol. 2007 Nov;157(5):545-59
pubmed: 17984234
Ann N Y Acad Sci. 1955 May 27;61(2):358-68
pubmed: 13249255
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Eur J Endocrinol. 2006 Apr;154(4):545-53
pubmed: 16556717
Br Med J. 1967 Apr 22;2(5546):205-7
pubmed: 6023103
Arq Bras Endocrinol Metabol. 2004 Oct;48(5):705-12
pubmed: 15761542
J Clin Endocrinol Metab. 2016 Nov;101(11):3888-3921
pubmed: 27736313
J Clin Endocrinol Metab. 1982 Sep;55(3):551-9
pubmed: 6284785
J Clin Endocrinol Metab. 2016 Oct;101(10):3691-3699
pubmed: 27490921
Clin Pharmacol Ther. 1961 Sep-Oct;2:615-35
pubmed: 13761949
Clin Endocrinol (Oxf). 2003 Sep;59(3):380-7
pubmed: 12919163
J Clin Endocrinol Metab. 1996 Aug;81(8):2865-73
pubmed: 8768843
Br Med J. 1952 Mar 15;1(4758):559-64
pubmed: 14904983
J Clin Endocrinol Metab. 2003 May;88(5):2061-9
pubmed: 12727955
Endocrine. 2020 Nov;70(2):412-420
pubmed: 32813212
J Clin Endocrinol Metab. 2012 Oct;97(10):E1938-42
pubmed: 22872686
BMC Endocr Disord. 2012 Jun 13;12:8
pubmed: 22695167
Clin Endocrinol (Oxf). 1995 Nov;43(5):623-9
pubmed: 8548948
Eur J Endocrinol. 2017 Sep;177(3):251-256
pubmed: 28596421
J Clin Endocrinol Metab. 2006 Oct;91(10):3954-61
pubmed: 16895963
J Clin Endocrinol Metab. 2001 Oct;86(10):4657-65
pubmed: 11600522
Front Horm Res. 2014;43:33-44
pubmed: 24943296
Eur J Clin Invest. 2017 Jul;47(7):494-503
pubmed: 28542805
J Clin Endocrinol Metab. 2016 Feb;101(2):364-89
pubmed: 26760044